ESR1 and breast carcinoma: These findings clearly demonstrate that PIs disrupt the cross-talk between HER2 and ERα signaling pathways, through mechanisms that differ from current therapeutic regimens and therefore might expand treatment opportunities for ER+/HER2+ and possibly also for other groups of breast cancer patients by breaking therapy resistance (Figure 4C and Figure 11).